#USA #INOVIO #Plymouth Meeting #Hemophilia A #DNA medicine

INOVIO to Participate in Key Scientific Conferences

INOVIO Pharmaceuticals, Inc., a pioneering biotechnology company, has announced its participation in two significant scientific events in November 2026. Specializing in developing DNA medicines aimed at treating various diseases, INOVIO is at the forefront of scientific innovation that addresses critical health issues such as HPV-related diseases, cancer, and infectious diseases.

Conference Details

1. Soft Bones Third International Scientific Meeting on Hypophosphatasia
- Location: New York
- Presentation: Rare Disease Protein Replacement Therapeutics - The Transformational Potential of Next-Gen DNA Medicine
- Date: Sunday, November 8, 2026

This conference will focus on advancing the understanding and treatment of hypophosphatasia, a rare metabolic bone disease. INOVIO’s involvement highlights its commitment to exploring next-generation DNA therapeutics that could transform treatment protocols.

2. World Federation of Hemophilia - New Technology Gene Therapy (NTGT) Workshop
- Location: Montreal
- Presentation: INO-D001 for Hemophilia A
- Date: Thursday, November 12, 2026

During this workshop, INOVIO will present its advancements regarding INO-D001, a promising therapy for Hemophilia A, which affects blood clotting. The insights shared at this event aim to educate stakeholders on the progress and future of gene therapy in treating hemophilia.

The Power of DNA Medicines

INOVIO leverages cutting-edge technology to optimize the design and delivery of DNA medicines. This technology enables the human body to produce its own disease-fighting agents effectively. With the growing interest in DNA-based therapies, INOVIO is well-positioned to lead in this space.

The presentations made at these conferences will not only underscore INOVIO’s innovative capabilities but also aim to engage the medical community in discussions around the future potential of DNA medicine.

About INOVIO

Founded with the vision to combat diseases through science, INOVIO is dedicated to developing and commercializing DNA medicines. Their innovative approaches hold great promise for treating not only HPV-related conditions but also other significant global health challenges. To learn more about INOVIO’s research and development initiatives, visit www.inovio.com.

Both events promise to be intellectually enriching opportunities for scientists, healthcare professionals, and investors alike, aiming to foster collaborative efforts in the biotechnology landscape. INOVIO’s active role in these discussions reinforces its mission to shape the future of medicine, especially in the fight against complex diseases.

As the dates draw near, further details regarding abstracts and presentations will be added to INOVIO’s events page, inviting participants to stay informed about the innovative breakthroughs being discussed.

By fostering engagement between industry leaders and researchers, INOVIO continues to drive forward the capabilities of DNA medicine, lightening the journey toward discovering viable solutions to pressing health issues.